Genetic Variation in BCL2 3′-UTR Was Associated with Lung Cancer Risk and Prognosis in Male Chinese Population

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Xu, Ping ^a,b   Liu, Li ^c   Wang, Jianzhong ^b   Zhang, Kai ^c   Hong, Xiaohua ^c   Deng, Qifei ^a   Xiang, Jingjun ^b   Zhang, Xiaomin ^a   He, Meian ^a   Wu, Tangchun ^a   Guo, Huan ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN IRON AND STEEL GROUP CORPORATION   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GENOMIC DNA; 3' UNTRANSLATED REGION; APOPTOSIS REGULATORY PROTEIN; PROTEIN BCL 2;

3' UNTRANSLATED REGION; ADULT; AGED; ALLELE; ARTICLE; BCL2 GENE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CHINESE; CONTROLLED STUDY; DOSE RESPONSE; FAMILY HISTORY; GENOTYPE; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; ASIAN CONTINENTAL ANCESTRY GROUP; ETHNOLOGY; GENE DOSAGE; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; LUNG TUMOR; MIDDLE AGED; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROGNOSIS; RISK FACTOR; SURVIVAL;

3' UNTRANSLATED REGIONS; AGED; ALLELES; APOPTOSIS REGULATORY PROTEINS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; GENE DOSAGE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RISK FACTORS; SMOKING; SURVIVAL ANALYSIS;

EID: 84881567258     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072197     Document Type: Article

References (36)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2008) Cancer statistics, 2008. CA Cancer J Clin 58: 71-96.
2. Herbst RS, Heymach JV, Lippman SM, (2008) Lung cancer. N Engl J Med 359: 1367-1380.
3. Godtfredsen NS, Prescott E, Osler M, (2005) Effect of smoking reduction on lung cancer risk. JAMA 294: 1505-1510.
4. Shivapurkar N, Reddy J, Chaudhary PM, Gazdar AF, (2003) Apoptosis and lung cancer: a review. J Cell Biochem 88: 885-898.
5. Youle RJ, Strasser A, (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 9: 47-59.
6. Azad N, Iyer A, Vallyathan V, Wang L, Castranova V, et al. (2010) Role of oxidative/nitrosative stress-mediated Bcl-2 regulation in apoptosis and malignant transformation. Ann N Y Acad Sci 1203: 1-6.
7. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR, (2010) The BCL-2 family reunion. Mol Cell 37: 299-310.
8. Leibowitz B, Yu J, (2010) Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther 9: 417-422.
9. Reed JC, (1997) Double identity for proteins of the Bcl-2 family. Nature 387: 773-776.
10. Pakunlu RI, Wang Y, Tsao W, Pozharov V, Cook TJ, et al. (2004) Enhancement of the efficacy of chemotherapy for lung cancer by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense: novel multicomponent delivery system. Cancer Res 64: 6214-6224.
11. Lin J, Lu C, Stewart DJ, Gu J, Huang M, et al. (2012) Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk. Carcinogenesis 33: 1699-1706.
12. Park JY, Park JM, Jang JS, Choi JE, Kim KM, et al. (2006) Caspase 9 promoter polymorphisms and risk of primary lung cancer. Hum Mol Genet 15: 1963-1971.
13. Ter-Minassian M, Zhai R, Asomaning K, Su L, Zhou W, et al. (2008) Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis 29: 2147-2152.
14. Guo H, Bai Y, Xu P, Hu Z, Liu L, et al. (2010) Functional promoter -1271G>C variant of HSPB1 predicts lung cancer risk and survival. J Clin Oncol 28: 1928-1935.
15. Sobin LH, Wittekind CH (2002) TNM classification of malignant tumors. 6th edition. New York: Wiley-Liss.
16. Kim DH, Xu W, Ma C, Liu X, Siminovitch K, et al. (2009) Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. Blood 113: 2517-2525.
17. Enjuanes A, Benavente Y, Bosch F, Martin-Guerrero I, Colomer D, et al. (2008) Genetic variants in apoptosis and immunoregulation-related genes are associated with risk of chronic lymphocytic leukemia. Cancer Res 68: 10178-10186.
18. Ferron PE, Bagni I, Guidoboni M, Beccati MD, Nenci I, (1997) Combined and sequential expression of p53, Rb, Ras and Bcl-2 in bronchial preneoplastic lesions. Tumori 83: 587-593.
19. Gao Q, Yang S, Kang MQ, (2012) Influence of survivin and Bcl-2 expression on the biological behavior of non-small cell lung cancer. Mol Med Report 5: 1409-1414.
20. Herbst RS, Frankel SR, (2004) Oblimersen sodium (Genasense bcl-2 antisense oligonucleotide): a rational therapeutic to enhance apoptosis in therapy of lung cancer. Clin Cancer Res 10: 4245s-4248s.
21. Lee JH, Jeon MH, Seo YJ, Lee YJ, Ko JH, et al. (2004) CA repeats in the 3'-untranslated region of bcl-2 mRNA mediate constitutive decay of bcl-2 mRNA. J Biol Chem 279: 42758-42764.
22. Zhu W, Shan X, Wang T, Shu Y, Liu P, (2010) miR-181b modulates multidrug resistance by targeting BCL2 in human cancer cell lines. Int J Cancer 127: 2520-2529.
23. Zhu W, Xu H, Zhu D, Zhi H, Wang T, et al. (2012) miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP. Cancer Chemother Pharmacol 69: 723-731.
24. Sacconi A, Biagioni F, Canu V, Mori F, Di Benedetto A, et al. (2012) miR-204 targets Bcl-2 expression and enhances responsiveness of gastric cancer. Cell Death Dis 3: e423.
25. Garbuzenko OB, Saad M, Pozharov VP, Reuhl KR, Mainelis G, et al. (2010) Inhibition of lung tumor growth by complex pulmonary delivery of drugs with oligonucleotides as suppressors of cellular resistance. Proc Natl Acad Sci U S A 107: 10737-10742.
26. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, et al. (1994) Paradoxical inhibition of solid tumor cell growth by bcl2. Cancer Res 54: 3714-3717.
27. Hirata H, Hinoda Y, Nakajima K, Kikuno N, Suehiro Y, et al. (2009) The bcl2-938CC genotype has poor prognosis and lower survival in renal cancer. J Urol 182: 721-727.
28. Knoefel LF, Werle-Schneider G, Dally H, Muller PJ, Edler L, et al. (2011) Polymorphisms in the apoptotic pathway gene BCL-2 and survival in small cell lung cancer. J Thorac Oncol 6: 183-189.
29. Nuckel H, Frey UH, Bau M, Sellmann L, Stanelle J, et al. (2007) Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. Blood 109: 290-297.
30. Park YH, Sohn SK, Kim JG, Lee MH, Song HS, et al. (2009) Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy. Clin Cancer Res 15: 2107-2115.
31. Moon JH, Sohn SK, Lee MH, Jang JH, Kim K, et al. (2010) BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients. Leuk Res 34: 166-172.
32. Gridelli C, Rossi A, Maione P, (2003) Treatment of non-small-cell lung cancer: state of the art and development of new biologic agents. Oncogene 22: 6629-6638.
33. Kim R, Emi M, Tanabe K, Toge T, (2004) Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer 101: 2491-2502.
34. Stabile LP, Siegfried JM, (2003) Sex and gender differences in lung cancer. J Gend Specif Med 6: 37-48.
35. Patel JD, (2005) Lung cancer in women. J Clin Oncol 23: 3212-3218.
36. Thomas L, Doyle LA, Edelman MJ, (2005) Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest 128: 370-381.